Table 1.
Clinicopathological characteristics of the patients.
| Characteristic | N (743) | (%) |
|---|---|---|
| Age | ||
| Median (range), years | 48.0 (22.0–83.5) | |
| Menopausal status | ||
| Pre-menopausal | 379 | (51.0) |
| Post-menopausal | 364 | (49.0) |
| Clinical T stage | ||
| T1-T2 | 518 | (69.7) |
| T3-T4 | 197 | (26.5) |
| Missing | 28 | (3.8) |
| Clinical node status | ||
| Negative | 444 | (59.8) |
| Positive | 279 | (37.5) |
| Missing | 20 | (2.7) |
| Histotypea | ||
| Invasive ductal carcinoma | 671 | (90.3) |
| Other histology typesb | 53 | (7.1) |
| Missing | 19 | (2.6) |
| Estrogen receptor statusa | ||
| Positive | 484 | (65.1) |
| Negative | 184 | (24.8) |
| Missing | 75 | (10.1) |
| HER-2 statusa | ||
| Positive | 160 | (21.5) |
| Negative | 508 | (68.4) |
| Missing | 75 | (10.1) |
| Ki-67 index (%)a | ||
| Median (range) | 26 (0–100) | |
| Chemotherapy regimens | ||
| Anthracycline plus taxane | 510 | (68.6) |
| Anthracycline-based regimens | 204 | (27.5) |
| Taxane-based regimens | 29 | (3.9) |
| pCR | ||
| Yes | 107 | (14.4) |
| No | 636 | (85.6) |
T tumor, pCR pathological complete response, HER-2 human epidermal growth factor receptor-2.
aHistopathological examination of the pre-treatment biopsy specimen.
bIncluding lobular, mucinous, papillary, metaplastic, and mixed tumors.